YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Studies on the Components of Valerian and Isovaleramide

Valerian의 구성성분 및 이소발레르아미드에 관한 연구

  • 박현정 (덕성여자대학교 약학대학) ;
  • 이상협 (덕성여자대학교 약학대학)
  • Received : 2009.11.24
  • Accepted : 2009.12.01
  • Published : 2010.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Valerian (Valeriana officinalis L.) is a perennial that has been used for medicinal purposes from the ancient times and valerian preparations including root and rhizome extracts are known to possess a variety of biological activities such as anticonvulsant, antidepressant, sleep aid, tranquilizer, and anti-HIV activities. Main components of the extracts were classified according to the structural features. Importantly, one of the main components, isovaleramide, has drawn our attention due to the concise structure, broad spectrum, and low toxicities. The general aspects including generation of this interesting molecule, a variety of activities, pharmacokinetic properties, derivatization, and fusion with other known drugs were described. Isovaleramide has been isolated from valerian probably as an isolation artifact after treatment of ammonia to prepare ammoniated tincture, and is known to exhibit anticonvulsant, anxiolytic, sedative, and sleep aid activities without distinct side effects such as excessive sedation and decreasing muscle tone. It was also found to be well absorbed into the circulation system without specific cytotoxicity and genotoxicity. The derivatives of isovaleramide, valpromide, valrocemide and valnoctamide were also briefly discussed.

Keywords

References

  1. Polydeonny, L. V., Juravleev, U. P. and Hlapseev, H. J. : Medicinal and aromatic plants of the USSR, their use, cultivation & processing. Kolos Press, Moscow, USSR, p. 360 (1979).
  2. Hobbs, C. : Valerian, a literature review. HerbalGram 21, 19 (1989).
  3. Bos, R. : Analytical and phytochemical studies on valerian and valerian based preparations. Offsetdrukkerij Ridderprint B. V., Ridderkerk, Groningen (1997).
  4. Murakami, N., Ye, Y., Kawanishi, M., Aoki, S., Kudo, N., Yoshida, M., Nakayama, E. E., Shioda, T. and Kobayashi, M. : New Rev-transport inhibitor with anti-HIV activity from Valerianae Radix. Bioorg. Med. Chem. Lett. 12, 2807 (2002). https://doi.org/10.1016/S0960-894X(02)00624-8
  5. Francis, A. J. P. and Dempster, R. J. W. : Effect of valerian, Valeriana edulis, on sleep difficulties in children with intellectual deficits: Randomized trial. Phytomedicine 9, 273 (2002). https://doi.org/10.1078/0944-7113-00110
  6. Houghton, P. J. : The scientific basis for the reputed activity of valerian. J. Pharm. Pharmacol. 51, 505 (1999). https://doi.org/10.1211/0022357991772772
  7. Andreatini, R., Sartori, V. A., Seabra, M. L. and Leite, J. R. : Effect of valepotriates (valerian extract) in generalized anxiety disorder: A randomized placebo-controlled pilot study. Phytother. Res. 16, 650 (2002). https://doi.org/10.1002/ptr.1027
  8. Miyasaka, L. S., Atallah A. N. and Soares, B. G. : Valerian for anxiety disorders. Cochrane Database Syst. Rev. 4. Art. No. CD004515 (2006).
  9. Hattesohl, M., Feistel, B., Sievers, H., Lehnfeld, R., Hegger, M. and Winterhoff, H. : Extracts of Valeriana officinalis L. s.l. show anxiolytic and antidepressant effects but neither sedative nor myorelaxant properties. Phytomedicine 15, 2 (2008). https://doi.org/10.1016/j.phymed.2007.11.027
  10. Circosta, C., De-Pasquale, R., Samperi, S., Pinoand, A. and Occhiuto, F. : Biological and analytical characterization of two extracts from Valeriana officinalis. J. Ethnopharmacol. 112, 361 (2007). https://doi.org/10.1016/j.jep.2007.03.021
  11. Ruggero, G. F., Varsi, M. and Smith, M. C. : Antiepileptic Drugs 4th ed., Raven Press, New York, p. 581 (1995).
  12. Nogrady, T. : Medicinal Chemistry: A biochemical approach 2nd ed., Oxford University Press, p. 225 (1988).
  13. Fonnum, F. and Morselli, P. L. : Psychopharmacology: The third generation of progress, Raven press, New York, p. 173 and 183 (1987).
  14. Letchamo, W., Ward, W., Heard, B. and Heard, D. : Essential oil of Valeriana officinalis L. cultivars and their antimicrobial activity as influenced by harvesting time under commercial organic cultivation. J. Agric. Food Chem. 52, 3915 (2004). https://doi.org/10.1021/jf0353990
  15. Eadie, M. J. : Could valerian have been the first anticonvulsant? Epilepsia 45, 1338 (2004). https://doi.org/10.1111/j.0013-9580.2004.27904.x
  16. Hassan, E., Tayebeh, R., Samaneh, E. T., Vahid, N. and Vali-OAllah, M. : Evaluation of some Iranian wild species from valerianaceae as commercial sources of valepotriates. J. Boil. Sci. 8, 549 (2008). https://doi.org/10.3923/jbs.2008.549.555
  17. Kumar, V. : Potential medicinal plants for CNS disorders: an overview. Phytother. Res. 20, 1023 (2006). https://doi.org/10.1002/ptr.1970
  18. Upton, R., Petrone, C., Swisher, D., Goldberg, A., McGuffin, M. and Pizzorno, N. D. : Valerian root, Valeriana officinalis, analytical, quality control and therapeutic monograph. American Herbal Pharmacopoeia (AHP) and Therapeutic Compendium (1999).
  19. Balandrin, M. F., Van Wagenen, B. C. and Cordell, G. A. : Valerian-derived sedative agents. II. Degradation of Valmanederived valepotriates in ammoniated hydroalcoholic tincutes. J. Toxicol.-Toxin Rev. 14, 165 (1995).
  20. Buckova, A., Grznar, K., Haladova, M. and Eisenreichova, E. : Active sbustances in Valeriana officinalis L. Cesk. Farm. 26, 308 (1977).
  21. Bos, R., Woerdenbag, H. J., Hendriks, H., Zwaving, J. H., De Smet, P. A. G. M., Tittel, G., Wikstrm, H. V. and Scheffer, J. J. C. : Analytical aspects of phytotherapeutic valerian preparations. Phytochem. Anal. 7, 143 (1996). https://doi.org/10.1002/(SICI)1099-1565(199605)7:3<143::AID-PCA284>3.0.CO;2-1
  22. Fuzzati, N., Wolfender, J. L., Hostettmann, K., Msonthi, J. D., Mavi, S. and Molleyres, L. P. : Isolation of antifungal valepotriates from Valeriana capense and the search for valepotriates in crude Valerianaceae extracts. Phytochem. Anal. 7, 76 (1996). https://doi.org/10.1002/(SICI)1099-1565(199603)7:2<76::AID-PCA288>3.0.CO;2-L
  23. Balandrin, M. F. and Van Wagenen, B. C. : Use of isovaleramide as a mild anxiolytic and mild sedative agent. WO 94-28888 (1994).
  24. Heybroek, M., Rule, G., Wells, D. S., Pesyan, A. and McCaffrey, J. : Identification and Quantitation of Isovaleramide Metabolites in Human Urine. American Association of Pharmaceutical Sciences, San Antonio, TX (2006).
  25. Teychenne, P. F., Walters, I., Claveria, L. E., Calne, D. B., Price, J., Macgillivary, B. B. and Gompertz, D. : The encephalopathic action of five-carbon-atom fatty acids in the rabbit. Clin. Sci. Molec. Med. 50, 463 (1976).
  26. Isoherranen, N., Yagen, B. and Bialer, M. : New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16, 203 (2003). https://doi.org/10.1097/00019052-200304000-00014
  27. Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Loiseau, P. and Perucca, E. : Progress report on new anticonvulsant drugs: a summary of the Fifth Eilat Conference. Epilepsy. Res. 43, 11 (2001).
  28. Artman, L. D. and Balandrin, M. F. : Treatment of spasticity, convulsions by isovaleric acid derivatives CNS depressants. WO 98-08498 (1998).
  29. Artman, L. D. : Migrain treatments including isovaleramide compounds and serotonin agonists. US patent Appl. US 0101655 A1 (2005).
  30. Artman, L. D. and Balandrin, M. F. : Composition comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID. WO 99-446238 (1999).
  31. Artman, L. D., Balandrin, M. F. and Smith, R. L. : Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound. WO 00- 51586 (2000).
  32. Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E. and Tomson, T. : Progress report on new anticonvulsant drugs: a summary of the Fifth Eilat Conference on new epileptic drugs. Epilepsy Res. 61, 1 (2004).
  33. Rogawski, M. A. : Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69, 273 (2006). https://doi.org/10.1016/j.eplepsyres.2006.02.004
  34. Abdelhameed, M. H., Balan, G., Hunter, J., Teitelbaum, P. and Wells, D. : Pharmacokinetics (PK) of NPS 1776 in normal healthy subjects. Annu. Meet. Am. Assoc. Pharm. Sci. Abst. 2039 (2000).
  35. Abdelhameed, M. H., Balan, G., Hunter, J., Teitelbaum, P. and Wells, D. : Pharmacokinetics (PK) of NPS 1776 after multiple oral doses in normal healthy subjects. Annu. Meet. Am. Assoc. Pharm. Sci. Abst. 460 (2001).
  36. Perucca, E. : Pharmacological and therapeutic properties of valproate. A summary after 35 years of clinical experience. CNS Drugs 16, 695 (2002). https://doi.org/10.2165/00023210-200216100-00004
  37. Bialer, M. and Yagen, B. : Valproic acid: second generation. Neurotherapeutics 4, 130 (2007). https://doi.org/10.1016/j.nurt.2006.11.007
  38. Loscher, W. : Basic pharmacology of valproate. A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16, 669 (2002). https://doi.org/10.2165/00023210-200216100-00003
  39. Peterson, G. M. and Maunton, M. : Valproate: a simple chemical with so much to offer. J. Clin. Pharm. Ther. 30, 417 (2005). https://doi.org/10.1111/j.1365-2710.2005.00671.x
  40. Bialer, M. : Clinical pharmacology of valpromide. Clin. Pharmacokinet. 20, 114 (1991). https://doi.org/10.2165/00003088-199120020-00003
  41. Payen, C., Frantz, P., Martin, O., Parant, F., Moulsma, M., Place, C. and Descotes, J. : Delayed toxicity following acute ingestion of valpromide. Hum. Exp. Toxicol. 23, 145 (2004). https://doi.org/10.1191/0960327104ht430oa
  42. Isoherranen, N., Woodhead, J. H., White, H. S. and Bailer, M. : Anticonvulsant profile of valrocemide (TV 1901): a new antiepileptic drug. Epilepsia 42, 831 (2001). https://doi.org/10.1046/j.1528-1157.2001.042007831.x
  43. Winkler, I., Blotnik, S., Shimshoni, J., Yagen, B., Devor, M. and Bailer, M. : Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146, 198 (2005).
  44. Barel, S., Yagen, B., Schurig, V., Soback, S., Pisani, F., Peruca, E. and Bailer, M. : Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and epileptic patients. Clin. Pharmcol. Ther. 61, 442 (1997). https://doi.org/10.1016/S0009-9236(97)90194-6